Compare CHWY & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHWY | BLCO |
|---|---|---|
| Founded | 2010 | 1853 |
| Country | United States | Canada |
| Employees | N/A | 13000 |
| Industry | Catalog/Specialty Distribution | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.1B |
| IPO Year | 2019 | 2022 |
| Metric | CHWY | BLCO |
|---|---|---|
| Price | $21.20 | $19.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 15 |
| Target Price | ★ $28.64 | $21.64 |
| AVG Volume (30 Days) | ★ 7.0M | 849.4K |
| Earning Date | 12-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $12,601,500,000.00 | $5,101,000,000.00 |
| Revenue This Year | $7.32 | $7.83 |
| Revenue Next Year | $6.75 | $5.90 |
| P/E Ratio | $49.71 | ★ N/A |
| Revenue Growth | 6.24 | ★ 6.47 |
| 52 Week Low | $17.40 | $14.44 |
| 52 Week High | $37.34 | $21.36 |
| Indicator | CHWY | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 74.71 |
| Support Level | $19.78 | $15.30 |
| Resistance Level | $22.31 | N/A |
| Average True Range (ATR) | 0.78 | 0.69 |
| MACD | 0.09 | 0.41 |
| Stochastic Oscillator | 56.77 | 77.03 |
Founded in 2011, Chewy is a leading e-commerce retailer of pet food, toys, supplies, and medications in North America. The firm offers a comprehensive selection of proprietary and third-party brands, anchored by its highly sticky autoship subscription program, which drives over 83% of its sales. Beyond core retail, Chewy is expanding into high-margin revenue streams, including its retail media network (Chewy Ads), specialized veterinary healthcare software, and brick-and-mortar veterinary clinics to further integrate customers into the Chewy ecosystem.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.